Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BCAX
SELLBicara Therapeutics Inc. · Healthcare · United States · $1.8B · Avg Vol: $23M/d
COMPANY DESCRIPTION
Bicara Therapeutics Inc. is a clinical-stage biotechnology company developing novel bifunctional therapeutics for cancer treatment. Its unique approach combines targeted drug delivery with immune stimulation, aiming for enhanced efficacy and reduced toxicity. Bicara is a niche biotech focused on innovative oncology drug development with a distinct mechanism of action.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.45 | -1.53 | -4.05 | -2.52 | — | -2.71 | -3.48 | -3.63 | — |
| Shares | 51.8M | 51.8M | 54.4M | 56.6M | +9.4% | 65.7M | — | — | — |
| Debt | 0 | 0.7M | 0.7M | 1.7M | 61.3% | 1.4M | — | — | — |
| Equity | -98.8M | -148.8M | 491.9M | 401.5M | -18.4% | — | — | — | — |
| Op CF | -32.1M | -45.6M | -74.8M | -106.8M | — | -116.2M | — | — | — |
| Inv CF | -0.2M | -0.6M | -9.0K | -318.5M | — | — | — | — | — |
| Fin CF | 31.7M | 272.5M | 334.0M | 32.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BCAX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc.(you) | $1.8B | 31 | SELL |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 30 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 32 | SELL |
| VIR | Vir Biotechnology, Inc. | $1.5B | 32 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 28 | SELL |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 26 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
| XNCR | Xencor, Inc. | $1.4B | 30 | SELL |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%